RayKnowChina Research Map
Shortlist0

Xinjiang Medical University

新疆医科大学

UrumqiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.1%Leads under 1 in 100 of China's research papers on NPC

Led 3 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025
ThemesRadiotherapy techniqueSide effects & quality of life

Hospitals counted here

  1. Affiliated Cancer Hospital of Xinjiang Medical University2
  2. Third Affiliated Hospital of Xinjiang Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.3%Leads about 1 in 79 of China's research papers on ESCC ▼ from 1.8%

Led 37 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
37
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 222025
ThemesMolecular markers & genomicsImmunotherapyRadiotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xinjiang Medical University29
  2. Affiliated Cancer Hospital of Xinjiang Medical University9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Oropharyngeal microbiome dysbiosis in esophageal squamous cell carcinoma: taxonomic shifts, metabolic reprogramming, and geographic disparities in a high-incidence cohort.2025PeerJFree full text
  2. Single-port inflatable mediastinoscopic esophagectomy is a cure for esophageal cancer patients: Case report.2022MedicineFree full text
  3. The value of complete blood count for the prognosis analysis of preoperative esophageal squamous cell carcinoma.2021BMC cancerFree full text
  4. 5-FU Resistance Facilitates Immune Evasion in Esophageal Squamous Cell Carcinoma Through ADAM10-Mediated PD-L1 Shedding and Tumour Microenvironment Remodelling.2026Immunology
  5. Prognostic Value of UBE2S, HIF-1α, and FOXM1 Expression in Esophageal Squamous Cell Carcinoma.2025Analytical cellular pathology (Amsterdam)Free full text
Trials on ClinicalTrials.gov5
  1. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  2. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  3. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  4. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  5. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.3%Leads under 1 in 100 of China's research papers on HCC

Led 42 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
42
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Hospitals counted here

  1. First Affiliated Hospital of Xinjiang Medical University22
  2. Affiliated Cancer Hospital of Xinjiang Medical University Counted in the group total13
  3. Second Affiliated Hospital of Xinjiang Medical University Counted in the group total2
  4. Fifth Affiliated Hospital of Xinjiang Medical University Counted in the group total1
  5. Affiliated Hospital of Xinjiang Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Controlling nutritional status score predicts posthepatectomy liver failure: an online interpretable machine learning prediction model.2025European journal of gastroenterology & hepatologyRCT
  2. Artificial intelligence-driven CT radiomics model predicts prognosis in TACE-refractory hepatocellular carcinoma.2026Abdominal radiology (New York)Free full text
  3. Hepatitis B-associated cirrhosis combined with multiple nodular fatty infiltrates of the liver: A rare benign disease misdiagnosed as hepatocellular carcinoma - a case report.2025MedicineFree full text
  4. Prediction of Ki-67 expression in hepatocellular carcinoma with a computed tomography (CT) extracellular volume-derived nomogram.2025Clinical radiology
  5. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  3. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  4. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  5. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  6. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Study siteStart 2018-07

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.3%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 27 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
27
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesChemotherapy & combined treatmentImaging & AIPeritoneal spread & advanced disease

Hospitals counted here

  1. First Affiliated Hospital of Xinjiang Medical University Counted in the group total10
  2. Affiliated Cancer Hospital of Xinjiang Medical University4
  3. Second Affiliated Hospital of Xinjiang Medical University Counted in the group total4
  4. Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University2
  5. Fourth Affiliated Hospital of Xinjiang Medical University Counted in the group total1
  6. Fifth Affiliated Hospital, Xinjiang Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Network pharmacology analysis and clinical efficacy study of Fuzi Lizhong Decoction combined with XELOX plus sintilimab in the treatment of advanced gastric cancer.2025MedicineFree full text
  2. Association Between CDK4/CDK6 Expression and Prognosis in Patients with Adenocarcinoma of Gastroesophageal Junction.2025Digestive diseases and sciences
  3. Short-term outcomes of robotic vs. laparoscopic surgery for gastric cancer after neoadjuvant therapy: a systematic review and meta-analysis.2025BMC cancerFree full text
  4. Diagnostic accuracy of radiomics-based machine learning for neoadjuvant chemotherapy response and survival prediction in gastric cancer patients: A systematic review and meta-analysis.2024European journal of radiology
  5. Comment on 'Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study'.2024International journal of surgery (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  4. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  5. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  6. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.4%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 10 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.2%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 1 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.3%Leads under 1 in 100 of China's research papers on Myeloma

Led 5 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025
ThemesRelapse & resistanceDrug combinationsDiagnosis, MRD & risk

Hospitals counted here

  1. First Affiliated Hospital of Xinjiang Medical University3
  2. Fourth Affiliated Hospital, Xinjiang Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.5%Leads under 1 in 100 of China's research papers on Aplastic anaemia New since 2021

Led 2 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesStem cell transplantInfection & supportive care

Hospitals counted here

  1. First Affiliated Hospital of Xinjiang Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
32.2%Leads about 1 in 3 of China's research papers on Hepatic echinococcosis

Led 49 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
49
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
10.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

Hospitals counted here

  1. First Affiliated Hospital of Xinjiang Medical University42
  2. Affiliated Cancer Hospital of Xinjiang Medical University4
  3. Fifth Affiliated Hospital of Xinjiang Medical University1
  4. Xinjiang Medical University Affiliated First Hospital1
  5. Xinjiang Medical University Affiliated First Hospital1
  6. Affiliated Hospital of Xinjiang Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.3%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 3 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Affiliated Cancer Hospital of Xinjiang Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov